EMBLA logo

Embla Medical hf. Stock Price

CPSE:EMBLA Community·DKK 11.6b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

EMBLA Share Price Performance

DKK 27.25
-4.95 (-15.37%)
DKK 33.30
Fair Value
DKK 27.25
-4.95 (-15.37%)
18.2% undervalued intrinsic discount
DKK 33.30
Fair Value
Price DKK 27.25
AnalystConsensusTarget DKK 33.30
AnalystLowTarget DKK 29.00
AnalystHighTarget DKK 39.10

EMBLA Community Narratives

·
Fair Value DKK 33.3 18.2% undervalued intrinsic discount

Analysts Lift Embla Medical hf Price Target on Stronger Growth and Improved Margins

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value DKK 29 6.0% undervalued intrinsic discount

Rising Regulatory And US Tariff Pressures Will Depress Market Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value DKK 39.1 30.3% undervalued intrinsic discount

Digital Healthcare And Aging Trends Will Expand Opportunities

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
DKK 33.3
18.2% undervalued intrinsic discount
Revenue
8.37% p.a.
Profit Margin
10.48%
Future PE
20.9x
Price in 2029
DKK 40.56
DKK 39.1
30.3% undervalued intrinsic discount
Revenue
9.74% p.a.
Profit Margin
10.62%
Future PE
25.94x
Price in 2028
DKK 47.92

Trending Discussion

No trending discussion available.

Updated Narratives

EMBLA logo

EMBLA: Buybacks And Tighter Assumptions Will Shape Measured Future Upside Potential

Fair Value: DKK 29 6.0% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
EMBLA logo

EMBLA: Recent Buybacks Will Support Future Upside Potential

Fair Value: DKK 33.3 18.2% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
EMBLA logo

Digital Healthcare And Aging Trends Will Expand Opportunities

Fair Value: DKK 39.1 30.3% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with flawless balance sheet.

0 Risks
5 Rewards

Embla Medical hf. Key Details

US$984.5m

Revenue

US$371.1m

Cost of Revenue

US$613.4m

Gross Profit

US$519.4m

Other Expenses

US$93.9m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 20, 2026
0.22
62.31%
9.54%
38.9%
View Full Analysis

About EMBLA

Founded
1971
Employees
4500
CEO
Sveinn Solvason
WebsiteView website
www.emblamedical.com

Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides osteoarthritis solutions that are designed to reduce pain and improve mobility for people living with osteoarthritis; and injury solutions for people recovering from fractures, ligament injuries, or need post-operative treatment. This segment also offers Unloader One, a range knee braces that relieve pain from knee osteoarthritis; and Unloader Hip, which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip. The Patient Care segment provides prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. The company serves orthopedic and prosthetic clinics, hospitals, and surgery centers. It sells its products through its direct sales networks and distributors. The company was formerly known as Össur hf. and changed its name to Embla Medical hf. in April 2024. Embla Medical hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Embla Medical hf. is a subsidiary of William Demant Invest A/S.

Recent EMBLA News & Updates

Narrative Update Jul 09

EMBLA: Buybacks And Tighter Assumptions Will Shape Measured Future Upside Potential

Analysts have reduced their price target for Embla Medical hf. from DKK 34.0 to DKK 29.0, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple.
Narrative Update Jun 24

EMBLA: Recent Buybacks Will Support Future Upside Potential

Analysts have kept their DKK price target for Embla Medical hf broadly steady, with only a marginal adjustment that reflects small tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Embla Medical hf reported completion of a share repurchase program covering 556,103 shares, equivalent to 0.13% of the company, for a total consideration of $2.6 million.

Recent updates

No updates